Hims & Hers (HIMS) Form 4: Director gets 6,623 RSUs with staggered vesting
Rhea-AI Filing Summary
Kare Schultz, a director of Hims & Hers Health, Inc. (HIMS), reported a grant of 6,623 restricted stock units (RSUs) on a Form 4 covering transactions dated 09/15/2025. The RSUs represent a contingent right to receive one share of Class A common stock per RSU and are subject to service-based vesting over three years with 1/3 vesting on 09/15/2025, 1/3 on 09/15/2026, and 1/3 on 09/15/2027. Following the reported transactions, the filing shows Schultz beneficially owns 15,741 shares of Class A common stock directly and 13,247 derivative securities (RSU-based) directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Positive
- Director alignment with shareholders: RSUs convert 1:1 to Class A shares, aligning Schultz's interests with shareholders over the vesting period
- Retention-focused vesting: Service-based vesting over three years helps retain board membership through 2027
- No cash outlay required: RSUs granted at $0 exercise price, indicating a compensation grant rather than a purchased position
Negative
- Contingent ownership: Only one-third vested immediately (09/15/2025), so full shares are not immediately available until 2027
- Potential dilution: The issuance of 6,623 RSUs will increase outstanding shares if and when vested and settled as common stock
Insights
TL;DR: Director received 6,623 RSUs with a three-year service-based vesting schedule; transaction appears routine and non-cash.
The grant of 6,623 RSUs to a company director aligns compensation with shareholder interests by tying value to equity performance and future service. The award vests in thirds over three years, which retains an employment/service linkage and staggers potential dilution. The filing shows both current direct holdings and RSU-based derivative holdings, clarifying immediate and contingent ownership levels. There is no cash exercise price and no sale or disposition reported, indicating this is a standard equity grant rather than a monetization event.
TL;DR: Standard director equity grant with multi-year vesting; governance implications are routine rather than material.
This Form 4 documents a typical equity compensation practice for non-employee directors. The service-based vesting schedule (one-third annually) promotes retention through 2027. The separate reporting of non-derivative shares and derivative RSU holdings provides transparency on Schultz's current voting/ownership versus contingent future shares. The signature by an attorney-in-fact is noted and the filing meets disclosure requirements; there are no departures, pledges, or unusual terms disclosed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 6,623 | $0.00 | -- |
| Exercise | Class A Common Stock | 6,623 | $0.00 | -- |
Footnotes (1)
- The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on September 15, 2025, (ii) 1/3 of the RSUs vesting on September 15, 2026, and (iii) 1/3 of the RSUs vesting on September 15, 2027.